Last Posted: Jun-07-2019 1PM
Last Posted: Jun 06, 2019
- Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers.
Vocka Michal et al. Cancers 2019 May 11(6) - Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci Maria Vittoria et al. The oncologist 2019 May - Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data.
Orucevic Amila et al. Breast (Edinburgh, Scotland) 2019 May 46116-125 - OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients.
Tevis S E et al. Annals of surgical oncology 2019 Mar 26(3) 815-820 - Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
Andre Fabrice et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 May JCO1900945 - Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity.
Fragoulakis Vasileios et al. American journal of human genetics 2019 May - Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.
Sparano Joseph A et al. The New England journal of medicine 2019 Jun - Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
Matikas A et al. Annals of oncology : official journal of the European Society for Medical Oncology 2019 Apr - Cost-effectiveness analysis of multigene expression profiling assays to guide adjuvant therapy decisions in women with invasive early-stage breast cancer.
Hannouf Malek B et al. The pharmacogenomics journal 2019 May - Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Zoe et al. JAMA network open 2019 May 2(5) e194428
.jpeg)
No hay comentarios:
Publicar un comentario